Objective: To report a case of diabetes mellitus (DM) associated with partial pancreatic agenesis and congenital heart disease (CHD) in a patient found to have a nonsense mutation of the GATA6 gene.
INTRODUCTION
Monogenic diabetes mellitus in adults represents a small and likely underdiagnosed percentage of the population of patients with diabetes. The clinical presentation of diabetes is variable but usually clinically distinct from type 1 or type 2 diabetes in that patients are typically young and non-obese with negative pancreatic antibodies. Due to development of next generation sequencing, clinical prevalence has been increasing as more is understood about the various genes that cause monogenic diabetes.
GATA6 is a gene that encodes a transcription factor with a key role in the development of several organ systems, as evidenced by the many congenital malformations that have been associated with GATA6 mutations (1) (2) (3) (4) (5) . GATA6 plays a role in gut, lung, pituitary and heart development, with broad expression in developing heart tissue (4, 6) . Mutations in GATA6 have been described in patients with a variety of congenital heart diseases, including both atrial and ventricular septal defects as well as conotruncal abnormalities (3, 6) . Mild hypoplasia of the right ventricle and the tricuspid valve have also been described in association with GATA6 mutations (1) . We present a patient with waxing and waning diabetes mellitus, tricuspid atresia, ventricular septal defect, transposition of the great vessels, and partial pancreatic agenesis found to have a GATA6 mutation.
CASE REPORT
A notable for a lack of acanthosis nigricans or skin tags. HbA1c this admission was 11.2% (99 mmol/mol).
Her initial blood glucose was 106 mg/dL. Review of her medical records revealed her congenital heart disease to be ventricular septal defect, transposition of the great vessels, and tricuspid atresia, which was surgically treated with a lateral tunnel Fontan procedure with last revision at age 12. She had not had follow-up with a cardiologist since the age of 18. Family history was largely unknown as the patient was adopted. A computed tomography (CT) scan of the abdomen was performed which showed Cardiology evaluation ruled out an acute process with a cardiac CT, which visualized a patent graft that was initially placed during Fontan procedure, and transesophageal echocardiogram showed normal ejection fraction. Work-up of cirrhosis including viral and autoimmune causes were negative and the patient denied any alcohol use. Thus, it was postulated that the most likely cause of her cirrhosis was chronic hepatic congestion in the setting of her surgically treated congenital heart disease. The presence of partial pancreatic agenesis and congenital heart disease along with a history of waxing and waning younger-onset insulin-dependent diabetes mellitus without a history of DKA prompted genetic testing for genes associated with monogenic diabetes mellitus, and a nonsense mutation (c.1242C>A, p.C414*) of the GATA6 gene was detected.
The patient was discharged on a basal-bolus insulin regimen of insulin glargine 6 units daily and insulin lispro 4 units three times daily and she was seen in follow up clinic with improved glycemic control. Three months after discharge, C-peptide was 1.62 u/mL (Normal: .80-3.85 u/mL) and a pituitary work up was unremarkable with ACTH, AM cortisol, IGF-1, prolactin, TSH and free T4 within normal limits. FSH and LH were not tested as the patient had an etonogestrel implant. GATA6 is a member of the GATA family of zinc finger transcription factors (1, 6) . Mutations in the GATA family have previously been associated with a variety of human diseases (6) . Pancreatic agenesis, a wide range of diabetes phenotypes, congenital heart defects, hepatic dysfunction, and malformations of the biliary, intestinal, and nervous system have been associated with GATA genes, which play a significant role in embryonic development (1) (2) (3) (4) (5) . GATA6 is thought to play a major role in cardiac development as well as the differentiation of alpha and beta islet cells in the pancreas.
DISCUSSION
De novo heterozygous inactivating mutations in GATA6 are the most common cause of pancreatic agenesis, indicating that GATA6 plays a key role in pancreatic development (1). These mutations have been shown to produce variable degrees of pancreatic dysfunction, ranging from lifethreatening neonatal diabetes to adult onset endocrine or exocrine dysfunction (2) . Our patient's exocrine function appeared be normal as she had no symptoms of malabsorption and a normal BMI.
Complete pancreatic agenesis presents as hyperglycemia in the first few days of life and is part of a spectrum of permanent neonatal diabetes. Our patient demonstrated partial pancreatic agenesis on CT scan (Figures 1, 2) . She was diagnosed with insulin-dependent diabetes mellitus, originally thought to be type 2, at the age of 20.
Treatment of monogenic diabetes is not well established. As a group, monogenic diabetes is thought to represent 2-5% of all cases of diabetes mellitus (7) . Presentation varies from permanent neonatal to maturity onset diabetes of the young (MODY) which can present as "type 1-like" or "type-2 like." Prevalence is likely underestimated due to under diagnosis. Up to 52% of MODY is attributed to genetic mutations in hepatocyte nuclear factor 1-alpha (HNF1-a) and treatment of choice in most of these patients is sulfonylurea treatment (8) . However, for a small subset of MODY, the preferred treatment is insulin. These instances are due to rare genetic mutations of hepatic nuclear factor-1 beta and neurogenic differentiation factor-1 causing pancreatic atrophy (9) (10) . In partial pancreatic agenesis, some beta islet cell function is maintained resulting in our patient's latent onset of diabetes and supported by her c-peptide at follow-up. The rarity of these genetic mutations, including GATA6, makes it difficult to estimate prevalence. In the future, we believe treatment will be tailored to individual mutation as more is understood about the mechanism of each mutation. We recommended treatment with basal-bolus insulin over other antihyperglycemic treatment options in our patient given the severity of her hyperglycemia. Her insulin requirements were modest during hospitalizations and at discharge, indicating preserved insulin sensitivity.
Several distinct GATA6 mutations have been described in the literature, without direct genotype-phenotype correlation. Our patient possessed a nonsense GATA6 mutation (c.1242C>A, p.C414*), previously described in a case report in which a patient had pancreatic agenesis, neonatal diabetes, renal dysfunction, atrial septal defect, ventricular septal defect (VSD), pulmonary stenosis, and patent ductus arteriosus (11) . In contrast, our patient had significantly less severe pancreatic manifestations and lacked any known renal dysfunction. Although both patients exhibited a VSD, tricuspid atresia with transposition of the great vessels were also present in our patient.
Tricuspid atresia (TA) is a rare cardiac malformation, representing only 1% of all congenital heart disease (12) (13) . TA is a cyanotic malformation that presents as an absence of the tricuspid valve, effectively removing the direct conduit between the right atrium and ventricle (12) . The pathogenesis of TA remains unknown, though an underlying genetic cause is suspected in at least some cases, supported by evidence from mice studies (14-16) as well as familial cases (17). A recent clinical genetic study of a patient with tricuspid atresia revealed two heterozygous mutations in NFATC1 (12), a gene previously discovered to be essential in valvular formation in mice (15-16). Exocrine function was thought to be maintained in our patient as she had no history of weight loss or steatorrhea. A fecal elastase was ordered but not done in our patient to screen for subclinical exocrine deficiency. Our patient initially presented to the emergency department for ascites as a result of previously undiagnosed cirrhosis in the absence of gallbladder pathology. Before GATA6 testing was obtained, her cirrhosis was deemed to be most likely secondary to chronic hepatic congestion in the setting of rightsided congenital heart disease. However, after diagnosis of her GATA6 mutation, we broadened our differential to include possible liver dysfunction or damage secondary to her genetic mutation. Although it is likely that her cirrhosis is secondary to chronic hepatic congestion, it is important to note that many patients with GATA6 mutations are known to have pathology of both the liver and biliary tree. Although hepatic complications secondary to gallbladder agenesis are most commonly encountered in these patients, reports of patients demonstrating both hepatic dysfunction and hepatomegaly in the absence of gallbladder or biliary tree pathology have been documented in the literature (3). Definitive diagnosis with hepatic biopsy was not performed as it would have been unlikely to change management in our patient. Pituitary agenesis with resultant hypopituitarism is another complication of GATA6 mutations and pituitary function testing should be performed in these patients (1, 2, 4) . Our patient's pituitary work-up was negative and the patient did not exhibit signs of diabetes insipidus.
Given the wide range of phenotypic presentations in patients with GATA6 mutations, further study is required to fully elucidate the contribution of GATA genes to normal embryonic development.
Due to the relative rarity of the mutation and somewhat recent availability of genetic testing, the prevalence of GATA6 as a cause of monogenic diabetes is unknown. Endocrinologists should consider testing for monogenic diabetes in younger, non-obese patients with negative pancreatic autoantibodies.
Work-up for GATA6 mutations specifically should also be entertained in the presence of congenital heart disease and pancreatic dysgenesis. Further studies are needed to determine the prevalence of GATA6 mutations causing monogenic diabetes outside of the neonatal period as well as to guide optimal therapeutic regimens and glycemic targets. 
CONCLUSION
GATA6 mutations are associated with a broad spectrum of diabetes phenotypes, pancreatic dysgenesis, and a variety of congenital heart diseases. A history of younger-onset non-obese diabetes with negative pancreatic antibodies, especially without a history of DKA despite years without insulin treatment, should prompt consideration of testing for monogenic diabetes, which revealed a GATA6 mutation in our patient. We believe that this case demonstrates the importance of testing for GATA6 mutations in any patient with this atypical diabetes presentation especially if accompanied by pancreatic dysgenesis and history of a congenital heart defect as documented in our patient.
